SP-siKRASG12D

SP-siKRASG12D is a preclinical gene therapy candidate designed to treat pancreatic ductal adenocarcinoma (PDAC). It consists of a small interfering RNA (siRNA) specifically targeting the KRAS G12D mutation, which is prevalent in the majority of PDAC cases. The siRNA is delivered using a patented superparamagnetic iron oxide nanoparticle (SPION) formulation, which facilitates cellular internalization and protects the genetic payload from degradation. By silencing the expression of mutant KRAS G12D, the drug inhibits oncogenic signaling pathways, including downstream targets such as YAP and PD-L1. This leads to the suppression of tumor cell proliferation, migration, and invasion, while inducing apoptosis through mechanisms involving Bax activation and PARP cleavage. Preclinical studies have demonstrated its efficacy in reducing tumor growth and metastasis in mouse models, particularly when used in combination with galectin-1 inhibitors.

Other names

superparamagnetic iron oxide nanoparticle-delivered KRASG12D siRNA